Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CytoTronics
AddedFeb 15, 2024
UpdatedJun 18, 2026
CytoTronics

CytoTronics

Seed

Optics-free imaging for drug discovery via CMOS electronics platform by CytoTronics.

HQ
Boston, MA, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize drug discovery, CytoTronics leverages its proprietary complementary metal-oxide-semiconductor (CMOS) electronics platform to enable optics-free imaging. The company's core vision is to provide high-throughput, single-cell resolution insights into cell functions, thereby accelerating the drug discovery process. Their flagship product, Pixel™, integrates cutting-edge technology with live-cell biology and data science, offering multiplexed live-cell readouts that seamlessly integrate with other systems and scale efficiently with cloud services.

CytoTronics has garnered attention within the scientific community, evidenced by their Pixel™ system receiving the New Product Award from the Society for Laboratory Automation and Screening (SLAS). This recognition underscores the innovative impact of their technology. By eliminating the need for traditional optics in imaging, CytoTronics has significantly advanced the capabilities of cellular analysis, positioning itself as a key player in the biotechnology and pharmaceutical industries.

CytoTronics - Similar Companies

Cytocybernetics logo

Cytocybernetics

Cytek Biosciences logo

Cytek Biosciences

cytekbio.com

Cytonus Therapeutics logo

Cytonus Therapeutics

cytonus.com

CytoMag logo

CytoMag

Plectix BioSystems logo

Plectix BioSystems

Cellanome logo

Cellanome

cellanome.com

CyOmics logo

CyOmics

CytoRecovery logo

CytoRecovery

cytorecovery.com

Cytomics Analytical logo

Cytomics Analytical

Celldom logo

Celldom

celldom.com

CytoViva logo

CytoViva

cytoviva.com

Cyto Wave Technologies logo

Cyto Wave Technologies

LumaCyte logo

LumaCyte

lumacyte.com

CytoAgents logo

CytoAgents

cytoagents.com

NanoCytomics logo

NanoCytomics

nano-cytomics.com

CytoTronics - Quick Facts

Who are CytoTronics' competitors?

Companies similar to CytoTronics include Cytocybernetics, Cytek Biosciences, Cytonus Therapeutics and CytoMag.

When was CytoTronics founded?

CytoTronics was founded in 2020.

Where is CytoTronics' headquarters located?

CytoTronics' headquarters is located in Boston, MA, US.

When was CytoTronics' last funding round?

CytoTronics' most recent funding round was for $9.3M (USD) in April 2022.

How much has CytoTronics raised to-date?

As of Apr 28, 2022, CytoTronics has raised a total of $9.3M (USD).

How many employees does CytoTronics have?

CytoTronics has 22 employees as of Feb 4, 2024.

CytoTronics - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cell Imaging
  • Drug Discovery
Tags
  • Biotech
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software